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Abstract: The suitability of samples for a given research depends on many variables, among 
which, the best preanalytical conditions for the type of test that should be carried out. Thus, 
standardization and harmonization of processing conditions for samples entering a particular 
study should be highly pursued to facilitate research collaborations among different institu-
tions and biological banks, allowing specimen comparison both for sample sharing and for the 
development of large-scale clinical trials. In this study, we review some issues and scenarios 
related to the adoption of the Sample PREanalytical Code, which deserve attention for a proper 
management of the samples and, ultimately, for maximizing the efficiency of the consistent 
investments required to set up biobanking resources.
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Introduction
Biobanks are defined as operational units that provide a service for the storage and 
management of biological material (organs, tissues, blood, cells, and fluids having an 
amount of DNA or RNA that allows genetic analysis) and associated personal data, 
in accordance with the codes of good practice, privacy law, and ethics guidelines as 
defined by the European Oviedo Convention.1
The increasing frequency of collaboration between research institutions and 
biobanks renders the knowledge of a biosample “quality” mandatory. The availability 
of biological samples has, in fact, assumed a crucial role in the field of biomedical 
research, from a basic to translational one, to assess predisposition to complex dis-
eases, and identification and validation of new diagnostic biomarkers, drug targets, or 
the improvement of monitoring strategies. All these tasks critically depend upon the 
availability of a large number of standardized biological specimens, and many research 
activities are seriously invalidated by the different methodological approaches employed 
during sample preparation.2 At present, in fact, the requirements for a specific intended 
use of the stored biomaterials are often lacking, as well as information on origin and 
preparation (preanalytical phase), and there are no standardized methods that can be 
used in comparative approaches between different institutions.3
In this review, we will consider some issues and scenarios related to the adoption of 
the Sample PREanalytical Code (SPREC), which deserve attention for a proper manage-
ment of biospecimens and, ultimately, for maximizing the efficiency of the consistent 
investments required to set up biobanking resources. Moreover, we will describe some 
information technology (IT) solutions developed by joint efforts within our institutions, 
aimed at facilitating the adoption of SPREC by all the organizations for managing 
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biosamples. These functionalities enable interested biological 
resource centers to establish shared searchable collections of 
SPRECs among a network of biobanking facilities.
A systematic literature review was performed by search-
ing in PubMed, Scopus, and Web of Science. The inclusion 
criteria regarded relevant research studies published in 
English. Furthermore, we extended our search on health care 
systems due to their similarity with the subject reported. For 
the selection of the search terms, we referred to previous 
literature reviews and the keywords of leading papers on the 
topic of biobanking as provided by the International Society 
for Biological and Environmental Repositories (ISBER) 
guidelines.
Sample quality and methodological 
pitfalls
The National Cancer Institute (NCI)/Office of Biorepositories 
and Biospecimen Research (OBBR) guidelines4 represent, 
together with the Biospecimen Research Network Sympo-
sium that took place in 2009,5 the first evidence of the urge 
to address the issue of biosample quality and of standard-
ized procedures for biospecimen collection, processing, 
and  storage. Members of the previous working groups par-
ticipated in Biospecimen Reporting for the Improved Study 
Quality (BRISQ) in 2011, which released recommendations 
intended for the reporting of data elements of human bio-
specimens (solid tissues and bodily fluids), running through 
the whole life cycle of a sample (from collection to analysis).6 
The recommendations gave birth to the BRISQ reporting item 
list, documenting sample preanalytical variables aimed at 
harmonizing the methods to trace information and facilitate 
effective inter- and intralaboratory specimen sharing/use. 
Furthermore, BRISQ efforts were focused on the standard-
ization and improvement of procedures for tissue processing 
to assess quality and suitability for research use, to identify 
quality control tools for tissues stored in biorepositories,2,7–9 
and to interpret and validate data from archived specimens. 
Tissue processing is of the utmost importance for the preser-
vation of both molecular and morphological integrity,10 and 
several preanalytical factors have been shown to significantly 
affect sample quality (eg, postmortem interval; cold ischemia 
time; specimen size; fixative buffer, delivery method, tem-
perature, and duration; and section thickness and storage) 
(for an extensive review see10).
Concomitant to the development of BRISQ recom-
mendation, the International Society for Biological and 
 Environmental Repositories Biospecimen Science Working 
Group endorsing the need of a deeper knowledge of the 
 preanalytical conditions of specimens used for research 
 activities generated the SPREC.11 The SPREC identifies the 
main preanalytical factors of clinical fluid and solid biospeci-
mens and their simple derivatives, which, together with its 
accompanying data, represent an essential part of its clini-
cal and scientific value.2 Accordingly, quality of specimens 
becomes a multidimensional concept that determines the 
scientific value and exchangeability potential for health care 
research. Recording information about a specimen and its pro-
cessing (eg, defining a set of features that are to be explicitly 
traced), in fact, gives the opportunity of choosing the right 
options for the right specimens and, at the same time, the right 
specimens for the target study (“fitness for purpose”).3 This 
concept finds its highest applications in the field of oncology, 
and applies both for sera and tissue samples.12
Thereby, biospecimen processing methods are recognized 
as a critical issue whose inappropriate application causes 
detrimental effects which are widely acknowledged.2
Among the many examples of methodological pitfalls, 
one may cite the important confounders in the interpretation 
of soluble CD40 ligand (sCD40L) level measurements due to 
preanalytical and analytical interferences.13 Indeed, platelet 
preactivation during the course of improper sample handling 
may substantially increase sCD40L levels,13,14 as well as keep-
ing samples at room temperature for prolonged periods before 
processing or freezing.15 Measurement of serum sCD40L 
levels is sensitive to all storage-associated preanalytic con-
ditions to such an extent that it has been proposed not only 
as a decay marker but also for the establishment of standard 
operating procedures in biobanking.13,15
Other methodological examples come from studies on 
vascular endothelial growth factor (VEGF), whose levels 
might be concealed in the presence of thrombocytopenia. 
To overcome this bias, VEGF levels should always be nor-
malized by platelet counts.16 Another interesting issue is 
represented by the use of ethylenediaminetetraacetic acid 
anticoagulated samples for mean platelet volume measure-
ment, which are biased by ethylenediaminetetraacetic acid-
induced platelet changes over time.17 This effect must be 
controlled by standardizing the duration between sampling 
and analysis, thus ensuring a relative homogeneity among the 
samples used and minimizing the differences in  analyses.18 
Furthermore, particular attention should be paid to the 
choice of samples to be analyzed for the research of lupus 
anticoagulant in studies on coagulation alterations occurring 
in conditions of acquired thrombophilia.19,20
Numerous sources of variability have been described for 
the nonobservance of the basic requirements for an optimal 
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sample, such as the contamination of the plasma with plate-
lets, the presence of activated platelets, or the concentration 
of calcium ions.21 It is evident that even a nonoptimal pre-
treatment (as might occur during the normal steps of plasma 
preparation), rather than a real error, would render the sample 
not fit for the purpose of the study.
Finally, several authors emphasize the importance of 
knowing the status of the subject who has agreed to provide 
the sample for the study, as some conditions can significantly 
interfere with the use of certain methods. For example, incon-
sistent results may be obtained with the use of functional tests 
of coagulation in carriers of the mutation R506Q FV Leiden 
and in case with the presence of lupus anticoagulant, increase 
of FVIII, or presence of factor VIIa.22
However, beside properly defined errors, the suitability of 
samples for a given research also depends greatly on the type 
of test that should be carried out. Thus, standardization and 
harmonization of processing conditions for samples enter-
ing a particular study should be highly pursued to facilitate 
research collaborations among different laboratories, both 
allowing specimen comparison for sample sharing, and for 
the development of large-scale clinical  trials. In this context, 
comprehensive guidelines for the best practices for managing 
biosamples in repositories have been provided by the ISBER 
guidance on best practices for collection, storage retrieval, 
and distribution of biological materials for research.23
Proper sample labeling
The urge to use “talking” codes rather than simple numeric 
ones stems from the need to mitigate errors in sample identi-
fiers during biosample mislabeling in research laboratories or 
biorepositories.24–26 The biospecimen publication guidelines 
of the NCI/OBBR4 first envisaged the need for more detailed 
information used for research activities.
As a possible support for this issue, ISBER has proposed 
and refined the SPREC, a labeling methodology which 
provides detailed information on the preanalytical condi-
tions that a single stored specimen has encountered during 
its manipulation.11,27 SPREC is a seven-element-long code, 
where each element corresponds to a punctual preanalytical 
variable and contains a string of letters (different for fluid 
or solid samples).11 This code can be integrated into the 
local institutional IT system (such as Biobank Information 
System [BIS]) and tracking databases so that the SPREC 
can share the same record and the information contained 
can be applied to all aliquots of the parent sample. The 
stand-alone application SPRECbase ensures SPREC 
output-coding and input-decoding of each specimen. Basic 
information concerning preanalytical data can be selected 
from SPREC tables by drop-down menus; the resulting 
SPREC will be stored in the local database, and can be 
easily retrieved.28,29 Also, 2D barcodes or quick response 
codes can provide plain text information combined with 
multiple links to online content (videos, photos,  hypertexts). 
This last coding system, although highly envisaged, would 
require the purchase of specialized software/application, 
which might represent a substantial investment both in time 
and  resources.30 Such implementation of the SPREC system 
is already under study in our institutions, and is going to 
be delivered together with its package and validated in a 
biological bank environment.
SPREC can be applied both to primary samples (samples 
directly collected from the donor) and to their derivative 
tubes, and provides different information on sample with-
drawal, processing, and storage for tissues and bodily fluids, 
all summarized in one single string on a sample label.11 
Obviously, this will be of particular help in the case of 
samples resulting from extensive technical manipulations 
that introduce preanalytical variables related to each labora-
tory’s standard operating procedures and operators. Indeed, 
the prevalence of errors in the selection of a sample by a 
laboratory that processes specimens manually is difficult 
to estimate. On the other hand, if the biological samples 
are SPREC-labeled by means of a barcode (as in the case 
of SPRECbase), any personnel handling the sample (even 
nontrained operators) can easily and explicitly obtain all the 
information associated with that preanalytical encoding by 
means of any reading device.
Since not all research laboratories are equipped with 
a management system shared with the central “core lab”, 
an application has been developed (SPRECware), and a 
server has been set up (SPRECbase), allowing for bar code 
(or quick response code) reading by means of any code-
scanning device: this provides the immediate decoding of 
the SPREC into the corresponding preanalytical information 
(Figure 1).28
In this scenario, checking whether a biological sample 
has characteristics that prevent its inclusion in a given study 
can be done by reading/scanning the SPREC. Moreover, if 
the information related to the nature of a biological sample 
is paired with the exact location within the biological bank, 
the construction of new studies and national and international 
collaborations is facilitated, with a remarkable saving of time 
otherwise spent for manual sample searching, and there is a 
significant increase of availability in terms of numbers and 
quality of samples as well as data related to them.
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Besides preanalytical variables, the whole biospecimen 
chain of custody, ie, the sample life cycle, should also be care-
fully monitored and checked. Indeed, this should occur even 
when minimizing the amount of time during which samples 
of a given batch undergo a drastic change in temperature 
(ie, when the batch is taken from the freezers at –80°C to 
insert/pick up a cryovial). Tracking temperature observations 
can undoubtedly help to rapidly identify artefacts during 
downstream sample assay.23
All samples (eg, sera, plasma, whole blood, urine, tissues) 
are stored in freezers at −80°C equipped with systems that 
allow the temporal marking of the stages of insertion/with-
drawal of the samples themselves. These systems, which may 
include radio-frequency identification (RFID)31 or bluechiip® 
technology (a passive wireless technology based on micro-
electromechanical systems),32 can overcome the possible 
problems stemming from the need to maintain the cold chain. 
RFID is a technology that uses communication via radio 
waves to exchange data between a reader  (interrogator) and an 
electronic tag attached to an object (label), for the purpose of 
identification and tracking.31 The cryotag uses a transmission 
contactless passive type and can be placed on the cryovial, 
on the wall of plates, on cryoboxes, and on the freezer door. 
Electronic information is then written on a portable remote 
writer/reader device that allows multiple and contemporary 
readings of RFID supports, and can associate a time record 
to every operation performed. Moreover, if samples are 
also mapped by software, this will allow their immediate 
localization and recognition, and will minimize the sample 
temperature-related alterations. Indeed, as an example of the 
detrimental effects of repeated freeze–thaw cycles,33,34 it has 
been reported that even one freeze–thaw cycle is capable of 
leading to substantial changes in the concentrations of serum 
analytes.35 The use of a RIFD-implemented SPREC will 
allow the operators to find and collect in the shortest possible 
time the required samples that might otherwise be exposed 
to sudden changes in temperature and consequent decay. It 
is obvious that this could ultimately lead to the acquisition 
of erroneous results due to no-longer-suitable samples. This 
is the case of plasma samples which, once frozen at −80°C, 
should be rapidly thawed at 37°C to prevent denaturating 
fibrinogen.36 The analysis of a sample not properly thawed 
would provide unreliable results.21
In general, the availability of samples of different quality 
levels in a biobank – if known and properly managed – can 
result in the optimization of costs and in the maximization 
of the outcome. Several procedures in sample preparation 
and maintenance have an intrinsic relevant cost. A crucial 
point is to avoid expensive procedures for specimens, which, 
at some point in their early life cycle, have been managed 
out of the best practices. In other words, the resulting final 
quality of the sample usually does not only depend on the 
last step, but rather on the “worst stage” over the whole 
life cycle.
In this scenario, a SPREC label which allows one to 
easily obtain most of the information associated with that 
preanalytical encoding can be very useful for:
•	 avoiding degradation of high-quality specimens due to a 
poor management;
•	 avoiding expensive handling procedures for specimens 
that do not fulfil the required quality criteria;
•	 selecting specimens which are suitable for inclusion in 
specific biomarker discovery projects.
For an easier selection of the suitable specimens, once 
the inclusion criteria have been defined, sample searching 
can be performed by partial “pattern-matching”. In other 
words, the user may specify only some of the fields (eg, type 
of sample, pre-centrifugation conditions, or elapsed time 
from sample acquisition), and the SPRECbase application 
would filter and list all the samples complying to such partial 
specification.28
Transfer of SPREC-labeled samples 
between laboratories/institutions
As part of the collaboration between research institutions, it 
is very frequent that a laboratory should send a large amount 
of samples to another laboratory. This may be the case in 
retrospective studies involving the analysis of a large segment 
of the population with special characteristics or belonging 
to a temporal situation or to a specific geographic area,37 
Figure 1 Generating sample Sample PReanalytical Code, with the corresponding barcode and quick response code.
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or of multicenter studies designed to determine the incidence 
and clinical relevance of a given condition.38
In the event of such large enlistments, it is not sufficient 
that the biological samples are provided with identifiers and 
paper documents containing the demographic information, 
medical history, and methodological description, since the 
amounts of data having to be consulted would be so elevated 
that it would expose the personnel of the “receiving” labora-
tory to manual mistakes during the compilation of the data-
base with sample-related information.
Conversely, if the laboratory that sends samples uses 
SPREC coding, then the laboratory which receives the 
samples can easily decode the SPREC of the sample batch 
and subsequently store this code on the local installation 
of SPRECbase.28 In this way, the transfer of samples and 
that of an integrated database with all the necessary pre-
analytics information can be achieved simultaneously, and 
the event of accidental mistakes due to manual handling of 
the information can be minimized. It is also very important 
to emphasize that the information related to a particular 
batch of samples will always be available so that the sample 
data can be retrieved at any time, facilitating the use of the 
samples for future scientific collaborations and allowing the 
update of the existing ones according to the new results.
If the facility receiving the SPREC-labeled samples 
does not adopt SPREC for internal purposes, it can still get 
interesting information about the samples by scanning the 
SPREC labels and decoding them, restoring the original 
preanalytical information in its own laboratory information 
system (Figure 2).
SPREC-based sample retrieval 
within a network of laboratories
This scenario applies well to all those trials that require the 
involvement of several research institutes due to either the 
objective difficulties of recruitment or the need for a multi-
center approach for external data validation. Both situations, 
requiring the exchange of large amounts of samples, allow 
for the translation of relevant findings into clinical practice. 
For this reason, it is desirable to establish a network of insti-
tutions sharing a labeling coding system in which context 
the availability and location of even few samples with given 
characteristics could be easily identified, thanks to the ability 
to consult a privileged common database (Figure 3).
The purpose of this desirable scenario would be the estab-
lishment of a SPREC database shared among a network of 
biorepositories. We can assume that SPREC-labeled samples 
are imported from every laboratory pertaining to the network 
where biological samples are made available to the entitled 
operators. This would allow for certain advantages in the 
planning of clinical trials: to avoid unnecessary duplication 
of research, to not wasting precious samples, to foster col-
laboration between researchers, and to optimize the distribu-
tion of research funds.
Future perspectives
The SPREC-coding system can be applied at various levels 
from handwritten to “high-tech” facilities to summarize 
both preanalytical and relevant post-analytical information. 
Moreover, SPREC has infinite applications, and in many 
Receiving BRC
Physical samples
Sample ID
Sample ID
Laboratory
information system
Preanalytics
summary
SPREC
SPRECbase
Figure 2 importing SPReC-coded samples in a biorepository.
Abbreviations: BRC, biological resource center; ID, identification; SPREC, Sample 
PReanalytical Code.
Figure 3 Searching SPReC-coded samples in a network of biorepositories.
Abbreviation: SPReC, Sample PReanalytical Code.
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different, not strictly clinical, environments. Presently, it has 
been successfully applied to algal culture collections, prov-
ing optional coding from the moment of sample collection to 
post-cryostorage manipulations.39 Future applications include 
its exploitation for a microbial culture bank within the Multi-
disciplinary Interinstitutional Biobank (BioBIM) facilities.
Thus, the “SPRECware architecture” previously described 
and here reported, does not represent an end point, but is sus-
ceptible to further implementation to increase its easiness to 
use and widespread diffusion among researchers.  Preliminary 
results have been obtained in a pivotal study specifically 
designed to facilitate the exchangeability of information using 
a web-based platform that does not require any software instal-
lation, and tests are being performed between the BioBIM 
of the IRCCS San Raffaele Pisana in Rome (the “sender” 
 laboratory) and the LC Campisi Laboratory Ltd in Sicily (the 
“receiver” laboratory). This has been made possible by the 
establishment of a permanent centralized web server, which 
is being implemented with the following features:
•	 SPREC-coding and -decoding servers with no installation 
requirements;
•	 SPREC-sharing server allowing enabled users to formu-
late queries with search/filtering capabilities;
•	 development of a downloadable version of SPRECbase.
These novel functionalities will ultimately provide the 
users with easy-to-use solutions for upload/download capa-
bilities to/from shared SPREC collections on a centralized 
server. Implementation with novel IT tools will also allow 
adjustments and timely updates to keep the SPREC’s optimal 
use in line with future technological developments.
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